Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Elastic NV (ESTC) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance

Elastic NVTrade
Recursion Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Elastic NV vs Recursion Pharmaceuticals Inc — how do they compare? Elastic NV trades at $75.22 (market cap $7.94B), while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.81B). The key difference: Elastic NV is far larger — about 4.4× Recursion Pharmaceuticals Inc's market cap, and Elastic NV is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

ESTCRXRX
Market Cap
$7.94B$1.81B
Sector
TechnologyHealth
52-Week High
$94.47$6.79
52-Week Low
$43.30$2.84
Enterprise Value
$7.16B$1.33B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Elastic NV

Elastic N.V. (ESTC) trades at $75.11, up 7.38% in the past 24 hours, with a bullish technical signal and strong analyst consensus. Recent earnings beats, including Q1 2026 EPS of $0.61 versus $0.561 expected, highlight operational strength. The company announced AI collaborations with OpenAI and AWS security distinctions, driving positive sentiment.

Outlook remains positive due to growth prospects in AI and security, but risks include high valuation multiples and ongoing legal investigations. The stock offers upside to the consensus price target of $74.21, though investors should weigh profitability improvements against competitive pressures.

Recursion Pharmaceuticals Inc

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Elastic NV

Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.

Read more on ESTC

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.

Read more on RXRX